Cargando…
Safety of Remdesivir for Patients 80 Years of Age or Older with Coronavirus Disease 2019 (COVID-19)
BACKGROUND AND OBJECTIVE: Although older patients with coronavirus disease 2019 (COVID-19) are at the high risk of exacerbation that requires treatment with remdesivir, the safety of this medication is unclear in clinical practice, especially among older patients. We aimed to retrospectively evaluat...
Autores principales: | Kanai, Osamu, Fujita, Kohei, Nanba, Kazutaka, Esaka, Naoki, Hata, Hiroaki, Seta, Koichi, Yasoda, Akihiro, Odagaki, Takao, Mio, Tadashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638643/ https://www.ncbi.nlm.nih.gov/pubmed/34859387 http://dx.doi.org/10.1007/s40266-021-00908-9 |
Ejemplares similares
-
Comparison of the acceptability and safety of molnupiravir in COVID-19 patients aged over and under 80 years
por: Fujita, Kohei, et al.
Publicado: (2023) -
Acute rhabdomyolysis in a young woman with moderate COVID-19
por: Fujita, Kohei, et al.
Publicado: (2021) -
525. Comparison of the acceptability and safety of molnupiravir in COVID-19 patients aged over and under 80 years
por: Fujita, Kohei, et al.
Publicado: (2023) -
Increasing Burden of Nursing Care on the Treatment of COVID-19 Patients in the Aging Society: Analyses During the First to the Third Wave of Pandemic in Kyoto City, Japan
por: Fujita, Kohei, et al.
Publicado: (2021) -
2632. Duration of viable SARS-CoV-2 shedding in immunocompromised COVID-19 patients during the widespread vaccination era
por: Kanai, Osamu, et al.
Publicado: (2023)